{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T11:08:45Z","timestamp":1768561725027,"version":"3.49.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"30","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DA041730"],"award-info":[{"award-number":["DA041730"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.vaccine.2020.05.027","type":"journal-article","created":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T01:00:42Z","timestamp":1589850042000},"page":"4704-4712","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Polymer-mediated delivery of vaccines to treat opioid use disorders and to reduce opioid-induced toxicity"],"prefix":"10.1016","volume":"38","author":[{"given":"Valeria","family":"Gradinati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Baruffaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santhi","family":"Abbaraju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Laudenbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rasidul","family":"Amin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Gilger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Poonam","family":"Velagaleti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Pravetoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.05.027_b0005","unstructured":"United Nations, World Drug Report 2019. 2019."},{"issue":"2","key":"10.1016\/j.vaccine.2020.05.027_b0010","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.7621","article-title":"Prevention of Prescription Opioid Misuse and Projected Overdose Deaths in the United States","volume":"2","author":"Chen","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2020.05.027_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.06.001","article-title":"Development of vaccines to treat opioid use disorders and reduce incidence of overdose","author":"Pravetoni","year":"2019","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.vaccine.2020.05.027_b0020","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1124\/pr.117.013904","article-title":"Conjugate Vaccine Immunotherapy for Substance Use Disorder","volume":"69","author":"Bremer","year":"2017","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.vaccine.2020.05.027_b0025","first-page":"1","article-title":"Biologics to treat substance use disorders: Current status and new directions","author":"Pravetoni","year":"2016","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"10.1016\/j.vaccine.2020.05.027_b0030","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1124\/jpet.112.201194","article-title":"Selective effects of a morphine conjugate vaccine on heroin and metabolite distribution and heroin-induced behaviors in rats","volume":"344","author":"Raleigh","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"issue":"12","key":"10.1016\/j.vaccine.2020.05.027_b0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184876","article-title":"Safety and efficacy of an oxycodone vaccine: Addressing some of the unique considerations posed by opioid abuse","volume":"12","author":"Raleigh","year":"2017","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.vaccine.2020.05.027_b0040","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1021\/jm3013745","article-title":"Reduced antinociception of opioids in rats and mice by vaccination with immunogens containing oxycodone and hydrocodone haptens","volume":"56","author":"Pravetoni","year":"2013","journal-title":"J Med Chem"},{"issue":"11","key":"10.1016\/j.vaccine.2020.05.027_b0045","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1002\/anie.201511654","article-title":"Combatting Synthetic Designer Opioids: A Conjugate Vaccine Ablates Lethal Doses of Fentanyl Class Drugs","volume":"55","author":"Bremer","year":"2016","journal-title":"Angew Chem Int Ed Engl"},{"issue":"1","key":"10.1016\/j.vaccine.2020.05.027_b0050","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1021\/acs.jmedchem.7b01427","article-title":"A Stable Heroin Analogue That Can Serve as a Vaccine Hapten to Induce Antibodies That Block the Effects of Heroin and Its Metabolites in Rodents and That Cross-React Immunologically with Related Drugs of Abuse","volume":"61","author":"Sulima","year":"2018","journal-title":"J Med Chem"},{"issue":"25","key":"10.1016\/j.vaccine.2020.05.027_b0055","doi-asserted-by":"crossref","first-page":"8601","DOI":"10.1021\/jacs.7b03334","article-title":"Development of a Clinically Viable Heroin Vaccine","volume":"139","author":"Bremer","year":"2017","journal-title":"J Am Chem Soc"},{"issue":"24","key":"10.1016\/j.vaccine.2020.05.027_b0060","doi-asserted-by":"crossref","first-page":"5927","DOI":"10.1007\/s00216-014-8035-x","article-title":"Characterization and optimization of heroin hapten-BSA conjugates: method development for the synthesis of reproducible hapten-based vaccines","volume":"406","author":"Torres","year":"2014","journal-title":"Anal Bioanal Chem"},{"key":"10.1016\/j.vaccine.2020.05.027_b0065","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.neuropharm.2018.06.026","article-title":"Prophylactic vaccination protects against the development of oxycodone self-administration","volume":"138","author":"Nguyen","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.vaccine.2020.05.027_b0070","first-page":"18(5)","article-title":"A conjugate vaccine attenuates morphine- and heroin-induced behavior in rats","author":"Li","year":"2014","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.vaccine.2020.05.027_b0075","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.pnpbp.2013.05.012","article-title":"A morphine conjugate vaccine attenuates the behavioral effects of morphine in rats","volume":"45","author":"Kosten","year":"2013","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.vaccine.2020.05.027_b0080","doi-asserted-by":"crossref","DOI":"10.1021\/acschemneuro.0c00064","article-title":"Evaluation of a Dual Fentanyl\/Heroin Vaccine on the Antinociceptive and Reinforcing Effects of a Fentanyl\/Heroin Mixture in Male and Female Rats","author":"Townsend","year":"2020","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.vaccine.2020.05.027_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2019.06.006","article-title":"Effectiveness and selectivity of a heroin conjugate vaccine to attenuate heroin, 6-acetylmorphine, and morphine antinociception in rats: Comparison with naltrexone","volume":"204","author":"Schwienteck","year":"2019","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.vaccine.2020.05.027_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107730","article-title":"Vaccine blunts fentanyl potency in male rhesus monkeys","volume":"158","author":"Tenney","year":"2019","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.vaccine.2020.05.027_b0095","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1021\/acschembio.6b00977","article-title":"An Advance in Prescription Opioid Vaccines: Overdose Mortality Reduction and Extraordinary Alteration of Drug Half-Life","volume":"12","author":"Kimishima","year":"2017","journal-title":"ACS Chem Biol"},{"issue":"22","key":"10.1016\/j.vaccine.2020.05.027_b0100","doi-asserted-by":"crossref","first-page":"9036","DOI":"10.1073\/pnas.1219159110","article-title":"Dynamic vaccine blocks relapse to compulsive intake of heroin","volume":"110","author":"Schlosburg","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.vaccine.2020.05.027_b0105","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1021\/acschemneuro.8b00079","article-title":"Efficacious Vaccine against Heroin Contaminated with Fentanyl","volume":"9","author":"Hwang","year":"2018","journal-title":"ACS Chem Neurosci"},{"issue":"14","key":"10.1016\/j.vaccine.2020.05.027_b0110","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1021\/jm200461m","article-title":"A vaccine strategy that induces protective immunity against heroin","volume":"54","author":"Stowe","year":"2011","journal-title":"J Med Chem"},{"issue":"9","key":"10.1016\/j.vaccine.2020.05.027_b0115","doi-asserted-by":"crossref","first-page":"11537","DOI":"10.1021\/acsomega.8b01478","article-title":"Improved Admixture Vaccine of Fentanyl and Heroin Hapten Immunoconjugates: Antinociceptive Evaluation of Fentanyl-Contaminated Heroin","volume":"3","author":"Hwang","year":"2018","journal-title":"ACS Omega"},{"issue":"42","key":"10.1016\/j.vaccine.2020.05.027_b0120","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.1016\/j.vaccine.2014.07.085","article-title":"Adjuvants for vaccines to drugs of abuse and addiction","volume":"32","author":"Alving","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.05.027_b0125","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jconrel.2018.02.006","article-title":"Immune response to antigen adsorbed to aluminum hydroxide particles: Effects of co-adsorption of ALF or ALFQ adjuvant to the aluminum-antigen complex","volume":"275","author":"Beck","year":"2018","journal-title":"J Control Release"},{"issue":"26","key":"10.1016\/j.vaccine.2020.05.027_b0130","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1016\/j.vaccine.2013.04.027","article-title":"Liposomes containing monophosphoryl lipid A: a potent adjuvant system for inducing antibodies to heroin hapten analogs","volume":"31","author":"Matyas","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.05.027_b0135","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41541-017-0013-9","article-title":"Heroin-HIV-1 (H2) vaccine: induction of dual immunologic effects with a heroin hapten-conjugate and an HIV-1 envelope V2 peptide with liposomal lipid A as an adjuvant","volume":"2","author":"Torres","year":"2017","journal-title":"npj Vaccines"},{"issue":"3","key":"10.1016\/j.vaccine.2020.05.027_b0140","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1021\/mp400631w","article-title":"Injection route and TLR9 agonist addition significantly impact heroin vaccine efficacy","volume":"11","author":"Bremer","year":"2014","journal-title":"Mol Pharm"},{"issue":"24","key":"10.1016\/j.vaccine.2020.05.027_b0145","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1016\/j.vaccine.2014.02.024","article-title":"Generation of a universal CD4 memory T cell recall peptide effective in humans, mice and non-human primates","volume":"32","author":"Fraser","year":"2014","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2020.05.027_b0150","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.bmc.2018.11.027","article-title":"Heat shock proteins: A dual carrier-adjuvant for an anti-drug vaccine against heroin","volume":"27","author":"Hwang","year":"2019","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.vaccine.2020.05.027_b0155","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/B978-0-12-420118-7.00014-7","article-title":"New directions in nicotine vaccine design and use","volume":"69","author":"Pentel","year":"2014","journal-title":"Adv Pharmacol"},{"issue":"4","key":"10.1016\/j.vaccine.2020.05.027_b0160","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.vaccine.2017.12.017","article-title":"A combined carrier-adjuvant system of peptide nanofibers and toll-like receptor agonists potentiates robust CD8+ T cell responses","volume":"36","author":"Rudra","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.05.027_b0165","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jconrel.2019.10.025","article-title":"Co-encapsulation of synthetic lipidated TLR4 and TLR7\/8 agonists in the liposomal bilayer results in a rapid, synergistic enhancement of vaccine-mediated humoral immunity","volume":"315","author":"Short","year":"2019","journal-title":"J Control Release"},{"issue":"11","key":"10.1016\/j.vaccine.2020.05.027_b0170","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1021\/acs.molpharmaceut.8b00592","article-title":"Preclinical Efficacy and Characterization of Candidate Vaccines for Treatment of Opioid Use Disorders Using Clinically Viable Carrier Proteins","volume":"15","author":"Baruffaldi","year":"2018","journal-title":"Mol Pharm"},{"issue":"2","key":"10.1016\/j.vaccine.2020.05.027_b0175","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1124\/jpet.118.253674","article-title":"A Fentanyl Vaccine Alters Fentanyl Distribution and Protects against Fentanyl-Induced Effects in Mice and Rats","volume":"368","author":"Raleigh","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"10.1016\/j.vaccine.2020.05.027_b0180","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1001\/archgenpsychiatry.2009.128","article-title":"Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial","volume":"66","author":"Martell","year":"2009","journal-title":"Arch Gen Psychiatry"},{"issue":"6","key":"10.1016\/j.vaccine.2020.05.027_b0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0002547","article-title":"A vaccine against nicotine for smoking cessation: a randomized controlled trial","volume":"3","author":"Cornuz","year":"2008","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.vaccine.2020.05.027_b0195","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/clpt.2010.317","article-title":"Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic","volume":"89","author":"Hatsukami","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.vaccine.2020.05.027_b0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096547","article-title":"Effect of currently approved carriers and adjuvants on the pre-clinical efficacy of a conjugate vaccine against oxycodone in mice and rats","volume":"9","author":"Pravetoni","year":"2014","journal-title":"PLoS ONE"},{"issue":"6","key":"10.1016\/j.vaccine.2020.05.027_b0205","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1021\/acs.molpharmaceut.8b01296","article-title":"Formulation and Characterization of Conjugate Vaccines to Reduce Opioid Use Disorders Suitable for Pharmaceutical Manufacturing and Clinical Evaluation","volume":"16","author":"Baruffaldi","year":"2019","journal-title":"Mol Pharm"},{"key":"10.1016\/j.vaccine.2020.05.027_b0210","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2018.1558697","article-title":"Alum adjuvant is more effective than MF59 at prompting early germinal center formation in response to peptide-protein conjugates and enhancing efficacy of a vaccine against opioid use disorders","author":"Robinson","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"7","key":"10.1016\/j.vaccine.2020.05.027_b0215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101807","article-title":"Effects of an oxycodone conjugate vaccine on oxycodone self-administration and oxycodone-induced brain gene expression in rats","volume":"9","author":"Pravetoni","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.05.027_b0220","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/401747","article-title":"Tailor-made pentablock copolymer based formulation for sustained ocular delivery of protein therapeutics","volume":"2014","author":"Patel","year":"2014","journal-title":"Journal of drug delivery"},{"issue":"2","key":"10.1016\/j.vaccine.2020.05.027_b0225","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1208\/s12249-014-0196-6","article-title":"Novel pentablock copolymer-based nanoparticulate systems for sustained protein delivery","volume":"16","author":"Patel","year":"2015","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.vaccine.2020.05.027_b0230","doi-asserted-by":"crossref","first-page":"2407459","DOI":"10.1155\/2016\/2407459","article-title":"Sustained Release of Protein Therapeutics from Subcutaneous Thermosensitive Biocompatible and Biodegradable Pentablock Copolymers (PTSgels)","volume":"2016","author":"Schaefer","year":"2016","journal-title":"J Drug Deliv"},{"key":"10.1016\/j.vaccine.2020.05.027_b0235","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.actbio.2014.11.050","article-title":"Effective polymer adjuvants for sustained delivery of protein subunit vaccines","volume":"14","author":"Adams","year":"2015","journal-title":"Acta Biomater"},{"issue":"1","key":"10.1016\/j.vaccine.2020.05.027_b0240","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1124\/jpet.111.189506","article-title":"An oxycodone conjugate vaccine elicits drug-specific antibodies that reduce oxycodone distribution to brain and hot-plate analgesia","volume":"341","author":"Pravetoni","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"10.1016\/j.vaccine.2020.05.027_b0245","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.2174\/092986652111141001122054","article-title":"Novel thermosensitive pentablock copolymers for sustained delivery of proteins in the treatment of posterior segment diseases","volume":"21","author":"Patel","year":"2014","journal-title":"Protein Pept Lett"},{"issue":"2","key":"10.1016\/j.vaccine.2020.05.027_b0250","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1124\/jpet.117.247049","article-title":"Opioid Dose- and Route-Dependent Efficacy of Oxycodone and Heroin Vaccines in Rats","volume":"365","author":"Raleigh","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.vaccine.2020.05.027_b0260","doi-asserted-by":"crossref","first-page":"5508","DOI":"10.1038\/s41598-018-23777-6","article-title":"Blocking interleukin-4 enhances efficacy of vaccines for treatment of opioid abuse and prevention of opioid overdose","volume":"8","author":"Laudenbach","year":"2018","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.vaccine.2020.05.027_b0265","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.nano.2016.07.015","article-title":"A nanoparticle-based nicotine vaccine and the influence of particle size on its immunogenicity and efficacy","volume":"13","author":"Zhao","year":"2017","journal-title":"Nanomedicine"},{"issue":"12","key":"10.1016\/j.vaccine.2020.05.027_b0270","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1166\/jbn.2015.2156","article-title":"Negatively Charged Carbon Nanohorn Supported Cationic Liposome Nanoparticles: A Novel Delivery Vehicle for Anti-Nicotine Vaccine","volume":"11","author":"Zheng","year":"2015","journal-title":"J Biomed Nanotechnol"},{"issue":"9","key":"10.1016\/j.vaccine.2020.05.027_b0275","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1038\/npp.2015.64","article-title":"Effects of the Nanoparticle-Based Vaccine, SEL-068, on Nicotine Discrimination in Squirrel Monkeys","volume":"40","author":"Desai","year":"2015","journal-title":"Neuropsychopharmacology"},{"issue":"24","key":"10.1016\/j.vaccine.2020.05.027_b0280","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1016\/j.vaccine.2014.02.027","article-title":"Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release","volume":"32","author":"Ilyinskii","year":"2014","journal-title":"Vaccine"},{"issue":"46","key":"10.1016\/j.vaccine.2020.05.027_b0285","doi-asserted-by":"crossref","first-page":"6332","DOI":"10.1016\/j.vaccine.2015.09.015","article-title":"The frequency of early-activated hapten-specific B cell subsets predicts the efficacy of vaccines for nicotine dependence","volume":"33","author":"Laudenbach","year":"2015","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2020.05.027_b0290","doi-asserted-by":"crossref","first-page":"5926","DOI":"10.4049\/jimmunol.1500385","article-title":"The frequency of naive and early-activated hapten-specific B cell subsets dictates the efficacy of a therapeutic vaccine against prescription opioid abuse","volume":"194","author":"Laudenbach","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2020.05.027_b0295","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jim.2014.01.010","article-title":"Hapten-specific na\u00efve B cells are biomarkers of vaccine efficacy against drugs of abuse","volume":"405","author":"Taylor","year":"2014","journal-title":"J Immunol Methods"},{"issue":"1","key":"10.1016\/j.vaccine.2020.05.027_b0300","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.cell.2019.12.027","article-title":"Slow Delivery Immunization Enhances HIV Neutralizing Antibody and Germinal Center Responses via Modulation of Immunodominance","volume":"180","author":"Cirelli","year":"2020","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.vaccine.2020.05.027_b0305","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/j.celrep.2019.10.008","article-title":"Rapid Germinal Center and Antibody Responses in Non-human Primates after a Single Nanoparticle Vaccine Immunization","volume":"29","author":"Havenar-Daughton","year":"2019","journal-title":"Cell Rep"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20306460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20306460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T17:40:22Z","timestamp":1762278022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20306460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":59,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0264410X20306460"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.05.027","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Polymer-mediated delivery of vaccines to treat opioid use disorders and to reduce opioid-induced toxicity","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.05.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}